Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lonza Group | London | Healthcare | Biotechnology & Medical Research | £37.93B | 58.8x | -1.25 | £510.79 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
arGEN X BV | London | Healthcare | Biotechnology & Medical Research | £22.76B | -140.6x | -2.22 | £379.14 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Genmab | London | Healthcare | Biotechnology & Medical Research | £13.94B | 23.2x | 6.02 | £220.45 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Qiagen NV | London | Healthcare | Biotechnology & Medical Research | £7.54B | 28.7x | -5.96 | £36.71 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Zealand Pharma | London | Healthcare | Biotechnology & Medical Research | £7.08B | -73x | -1.75 | £100.66 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Morphosys AG | London | Healthcare | Biotechnology & Medical Research | £2.16B | -5.2x | 0.01 | £56.38 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
BB Biotech L | London | Healthcare | Biotechnology & Medical Research | £2.10B | 7.8x | 0.04 | £38.11 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
AddLife | London | Healthcare | Biotechnology & Medical Research | £1.36B | 160.9x | -2.27 | £11.20 | 30.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Genus | London | Healthcare | Biotechnology & Medical Research | £1.21B | 36.6x | -10 | £18.46 | 5.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Corbus Pharmaceuticals Holdings | London | Healthcare | Biotechnology & Medical Research | £474.70M | -9x | -0.39 | £44.12 | 127.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
PureTech Health | London | Healthcare | Biotechnology & Medical Research | £423.12M | -9.6x | 0.24 | £1.78 | 2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Oxford BioMedica | London | Healthcare | Biotechnology & Medical Research | £387.29M | -2.3x | 0.01 | £3.68 | 5.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Avacta Group | London | Healthcare | Biotechnology & Medical Research | £257.67M | -7.8x | -0.29 | £0.72 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Allergy Therapeutics | London | Healthcare | Biotechnology & Medical Research | £228.79M | -1.6x | -0.15 | £0.05 | -5.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Inovio Pharmaceuticals | London | Healthcare | Biotechnology & Medical Research | £227.24M | -2x | -0.04 | £8.65 | 112.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Bioventix | London | Healthcare | Biotechnology & Medical Research | £224.45M | 25.9x | 12.71 | £43 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Hvivo | London | Healthcare | Biotechnology & Medical Research | £202.82M | 12.7x | 0.01 | £0.30 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
4BASEBIO UK SOCIETAS | London | Healthcare | Biotechnology & Medical Research | £188.88M | -25.1x | 0.5 | £14.40 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Faron Pharmaceuticals Oy | London | Healthcare | Biotechnology & Medical Research | £159.17M | -3.9x | -0.64 | £1.52 | 3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Scancell | London | Healthcare | Biotechnology & Medical Research | £131.54M | -12x | -0.59 | £0.14 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Futura | London | Healthcare | Biotechnology & Medical Research | £102.63M | -15.2x | 1.86 | £0.34 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Biotec Pharmacon | London | Healthcare | Biotechnology & Medical Research | £92.72M | 72.2x | £1.67 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Verastem | London | Healthcare | Biotechnology & Medical Research | £90.54M | -0.7x | -0.27 | £2.30 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Transgene | London | Healthcare | Biotechnology & Medical Research | £90.29M | -4.8x | -0.15 | £0.94 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Batm Advanced Comm | London | Healthcare | Biotechnology & Medical Research | £89.77M | -593.6x | 3.35 | £0.20 | -4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Poolbeg Pharma | London | Healthcare | Biotechnology & Medical Research | £63.25M | -17.2x | -1 | £0.13 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Novacyt SA | London | Healthcare | Biotechnology & Medical Research | £35.10M | -1.2x | 0.11 | £0.50 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
OncoCyte | London | Healthcare | Biotechnology & Medical Research | £34.91M | -0.7x | -0.02 | £2.48 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Sareum | London | Healthcare | Biotechnology & Medical Research | £33.68M | -5.1x | 0.17 | £0.32 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Incanthera | Aquis Exchange | Healthcare | Biotechnology & Medical Research | £30.28M | -12.2x | 0.38 | £0.31 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |